Early anti-VEGF Therapy Intervention for Retinal Vein Occlusion

Early anti-VEGF Therapy Intervention for Retinal Vein Occlusion - Early anti-VEGF Therapy Intervention for RVO

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026173

Enrollment

Registered

2017-02-16

Start date

2017-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic retinal vein occlusion with best corrected visual acuity of 20/40 or better, at least 3 months before enrollment.

Exclusion criteria

Exclusion criteria: 1. prior laser treatment, surgery, local steroid injection or anti-VEGF drug administration 2. bilateral retinal vein occlusion 3. uncontrolled glaucoma 4. uncontrolled systemic hypertension 5. other retinal disorders

Design outcomes

Primary

Measure	Time frame
Mean change from baseline best corrected visual acuity and macular retinal sensitivity at month 12.	—

Secondary

Measure	Time frame
Mean number of intravitreal injection at month 12. Mean change from baseline central retinal thickness (CRT) at month 12. Mean change from baseline best corrected visual acuity and macular retinal sensitivity at month 6. ocular serious adverse event.	—

Countries

Japan

Contacts

Public ContactKentaro Kojima

Kyoto Prefectural University of Medicine Ophthalmology

kenkojim@koto.kpu-m.ac.jp075-251-5578

Outcome results